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K e y  M e s s a g e 
A brief, tailored intervention was not effective in 
promoting quitting or reducing smoking in smokers 
with diabetes mellitus. The intervention also did not 
improve glycaemic control of these patients at 12 
months.
A brief, tailored smoking cessation intervention 
for smokers with diabetes mellitus in Hong Kong
TH Lam *, WHC Li, MP Wang, YTY Cheung, DYT Cheung, KY Ho, KCB Tan, SSC Chan
Introduction
Diabetes mellitus (DM) is an epidemic, chronic, non-
communicable disease. The number of patients with 
DM worldwide is expected to reach nearly 552 million 
by 2030. In Hong Kong, >90% of these patients are 
diagnosed as having type 2 DM, and 10.4% of them 
smoke.1 Continuous smoking increases the risk of 
cardiovascular disease, diabetic nephropathy, stroke, 
and amputation. In 2014, the American Diabetes 
Association strongly recommended to include 
interventions for smoking cessation as standard 
medical care for patients with type 2 DM to minimise 
health risks and control glycaemic levels. The best 
moment for initiating smoking cessation is at the 
medical appointment in the DM outpatient clinic. 
Health care professionals can use this opportunity 
to encourage smokers with DM to quit smoking. 
Nonetheless, our recent qualitative study of Hong 
Kong Chinese smokers with DM showed that 
these smokers had many misconceptions about the 
association between smoking and DM.2 They were 
reluctant to quit smoking and did not consider that 
the risks of continuous smoking could hinder their 
treatment efficacy and promote DM complications.
 We performed a randomised controlled trial 
to examine the effectiveness of a brief, low-cost, 
stage-matched smoking cessation intervention to 
motivate smokers with type 2 DM to quit smoking 
and minimise their health risks. Subjects in the 
intervention group received a 20-min face-to-face 
individualised counselling session, a DM-specific 
leaflet, and a self-help pamphlet on smoking. 
Booster talks were given at 1-week and 1-month 
follow-ups via telephone by nurse counsellors 
trained in smoking cessation. Subjects in the control 
group received usual care and a self-help pamphlet 
as a placebo. Data were collected at 1 week and at 
1, 3, 6 and 12 months by the nurse counsellors via 
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telephone. Biochemical validation was conducted 
at 12 months on the subjects who claimed that 
they had quit smoking. We hypothesised that the 
subjects in the intervention group would have 
higher rates of self-reported and biochemically 
validated smoking cessation, higher rates of smoking 
reduction and better glycaemic control (as measured 
by haemoglobin A1c [HbA1c] levels) at 12 months, 
compared with the control group subjects.
Results
From 2012 to 2014, 557 subjects (mean age, 55 years; 
nearly 90% were men) were recruited from different 
diabetic clinics of nine major hospitals in Hong Kong 
and randomised to the intervention (n=283) and 
control (n=274) group. More than half of them had 
attained a secondary education and were employed. 
On average, the subjects had smoked for 38 years 
and consumed 14 cigarettes daily. Over 70% of them 
were in the pre-contemplation stage of quitting 
and perceived themselves to be in good health. The 
results of an intention-to-treat analysis indicated 
that the intervention and control group did not 
differ significantly in the 7-day point-prevalence 
(9.2% vs 13.9%) or secondary outcomes including a 
biochemically validated rate of smoking cessation at 
12 months, stages of readiness to quit, and number 
of attempts to quit lasting at least 24 hours. Although 
the control group had a significantly higher rate of 
self-reported smoking reduction at 3 months (16.8% 
vs 10.2%, p=0.02), the two groups did not differ 
significantly at the 6- and 12-month follow-ups.
Discussion
The overall results showed no significant differences 
between the two groups, as nearly 80% of the 
patients thought that they were healthy and not 
in urgent need to quit smoking. This is consistent 
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with another study in which smokers with DM 
in the pre-contemplation stage were reluctant to 
receive smoking cessation intervention.3 In addition, 
our subjects might have been hardcore smokers, 
so the brief intervention might not have been 
sufficient or intensive enough to trigger quitting. 
Although there are no standard criteria to define 
hardcore smokers, six characteristics are known 
for hardcore smokers.4 Our subjects fulfilled three 
of them: regular smoking for 5 years or more, lack 
of intention to quit, and smoking daily. Besides, 
our subjects smoked up to 14 cigarettes per day, 
which also nearly fulfilled another characteristic of 
smoking 15 cigarettes/day. Our intervention could 
only point out the association between DM and 
smoking but not the causation, which might not be 
strong enough to motivate subjects to quit smoking. 
In a logistic regression analysis of the predictors 
of smoking cessation, subjects with higher daily 
cigarette consumption were more likely to fail to 
quit (odds ratio [OR]=0.93, 95% confidence interval 
[CI]=0.89-0.98). This information could be useful 
for healthcare professionals to estimate the quit rate 
and thus strengthen the intervention, as there was 
no association observed between past attempts at 
quitting and the final rate of quitting.
 Quitters and non-quitters did not differ 
significantly in HbA1c levels at 12 months (7.96% 
vs 7.99%), but non-quitters had a decreasing trend 
compared with baseline (OR=0.83, 95% CI=0.71-
0.97) after adjusting for confounders such as sex, 
age, and abstinence at 12 months. One possible 
explanation is that it is difficult to determine whether 
HbA1c levels respond to smoking cessation after 
12 months. Some studies found that HbA1c levels 
require 3 years to respond to changes in smoking 
status, and the reduction in health risk in quitters 
with DM is only apparent after 5 years of smoking 
cessation. Thus, a longitudinal study is needed to 
monitor the HbA1c level among smokers with DM.
Limitations
The results of this study may not be generalisable to all 
patients with DM, as only those who smoked two or 
more cigarettes daily were included. We encountered 
difficulties in recruitment as the prevalence of 
smoking was low in those who presented to DM 
outpatient clinics. An early stop to recruitment was 
recommended by the Independent Data Monitoring 
Committee after an interim analysis showed that 
no further benefit could be seen in the intervention 
group under continuous recruitment. We also had 
difficulties in collecting data on HbA1c levels from 
the clinics; this led to non-significant findings due to 
missing data.
Recommendations
We suggest the use of stronger warnings on the 
health risks of smoking to motivate smokers with 
DM, particularly hardcore smokers, to quit. Patients 
may see smoking cessation as beneficial to their 
health in the long run. We also recommend that the 
causation between smoking and DM complications 
be emphasised. A longitudinal study would provide 
more data on the improvement in glycaemic control 
and the reduction in the complications of DM after 
smoking cessation.
Conclusions
A brief, tailored intervention was not effective in 
promoting quitting or reducing smoking in smokers 
with DM. The intervention also did not improve 
glycaemic control of these patients at 12 months.
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